Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN DAWN HARTVICKSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679532659
CMS profile
303021
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$259.38

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.38 18

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN DAWN HARTVICKSON

NPI 1679532659 · CMS profile ID 303021

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $259.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $23.6112/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748977129 CMS
Allergan, Inc. $20.8611/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723693163 CMS
Amgen Inc. $14.4810/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289593 CMS
Merck Sharp & Dohme Corporation $13.1009/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747763915 CMS
Eisai Inc. $14.2909/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751221001 CMS
Eisai Inc. $23.8606/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751213831 CMS
AstraZeneca Pharmaceuticals LP $11.9706/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735855653 CMS
Allergan, Inc. $18.5906/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723693161 CMS
Novo Nordisk Inc $11.0606/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744764111 CMS
Kowa Pharmaceuticals America, Inc. $16.9105/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716729595 CMS
Novo Nordisk Inc $12.3305/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744693691 CMS
Astellas Pharma US Inc $16.4703/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718331571 CMS
Merck Sharp & Dohme Corporation $8.0602/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747692269 CMS
PFIZER INC. $1.1102/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743695758 CMS
PFIZER INC. $6.0602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743695905 CMS
Amgen Inc. $20.8801/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289595 CMS
Novartis Pharmaceuticals Corporation $13.1701/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725791995 CMS
AstraZeneca Pharmaceuticals LP $12.5701/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735919093 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $349.87 24
PY2020 $259.38 18
PY2021 $867.92 59
PY2022 $1,012.70 73
PY2023 $2,574.33 71
PY2024 $862.16 54
PY2025 $813.93 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,207.90 39
PY2024 Principal investigator $344,898.92 54
PY2023 Principal investigator $702,129.77 95
PY2022 Principal investigator $153,146.27 62
PY2021 Principal investigator $143,310.07 45
PY2020 Principal investigator $223,270.91 168
PY2019 Principal investigator $302,825.41 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,080.00 12/31/2021 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES LLC
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 789016717
Principal investigator 1 Merck Sharp & Dohme Corporation $15.86 12/31/2021 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 848761629
Principal investigator 1 Merck Sharp & Dohme Corporation $12,096.04 12/31/2021 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 848761891
Principal investigator 1 PFIZER INC. $3,784.80 12/23/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832569789
Principal investigator 1 GlaxoSmithKline, LLC. $1,510.20 12/21/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809496787
Principal investigator 1 GlaxoSmithKline, LLC. $2,236.50 12/15/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809517291
Principal investigator 1 GlaxoSmithKline, LLC. $1,656.90 11/24/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809537553
Principal investigator 1 PFIZER INC. $1,251.71 11/23/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832734393
Principal investigator 1 GlaxoSmithKline, LLC. $1,078.20 11/17/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486125
Principal investigator 1 GlaxoSmithKline, LLC. $2,223.90 11/17/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809517285
Principal investigator 1 PFIZER INC. $1,892.40 11/05/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832691249
Principal investigator 1 Merck Sharp & Dohme Corporation $17,833.67 11/03/2021 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 848761885
Principal investigator 1 GlaxoSmithKline, LLC. $1,639.80 10/20/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809537547
Principal investigator 1 PFIZER INC. $1,892.40 10/08/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832875097
Principal investigator 1 PFIZER INC. $1,563.52 09/22/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832899261
Principal investigator 1 GlaxoSmithKline, LLC. $1,288.80 09/15/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809522895
Principal investigator 1 PFIZER INC. $3,955.97 09/04/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832704481
Principal investigator 1 GlaxoSmithKline, LLC. $4,700.00 09/02/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486133
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.90 08/24/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809492463
Principal investigator 1 PFIZER INC. $2,296.80 08/06/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832849629
Principal investigator 1 GlaxoSmithKline, LLC. $1,803.60 07/27/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486123
Principal investigator 1 PFIZER INC. $388.22 07/20/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832694411
Principal investigator 1 GlaxoSmithKline, LLC. $1,399.50 07/14/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809493867
Principal investigator 1 SANOFI PASTEUR INC. $2,687.57 07/09/2021 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
VAD00001 Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers No dispute reported 06/30/2026 838355955
Principal investigator 1 GlaxoSmithKline, LLC. $1,324.80 07/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809493865
Principal investigator 1 PFIZER INC. $10,784.15 06/23/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832711307
Principal investigator 1 Allergan, Inc. $1,800.00 06/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789016709
Principal investigator 1 Allergan, Inc. $525.00 06/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789016711
Principal investigator 1 Allergan, Inc. $575.00 06/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789016713
Principal investigator 1 GlaxoSmithKline, LLC. $1,335.60 05/19/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809513793
Principal investigator 1 GlaxoSmithKline, LLC. $1,153.80 05/12/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809492487
Principal investigator 1 PFIZER INC. $5,677.20 04/24/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832848367
Principal investigator 1 GlaxoSmithKline, LLC. $1,687.50 04/21/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809485613
Principal investigator 1 GlaxoSmithKline, LLC. $1,728.90 04/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809513799
Principal investigator 1 PFIZER INC. $6,065.42 03/24/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832918119
Principal investigator 1 GlaxoSmithKline, LLC. $1,329.30 03/17/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809493847
Principal investigator 1 PFIZER INC. $1,892.40 03/05/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832713383
Principal investigator 1 GlaxoSmithKline, LLC. $1,803.60 02/23/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486435
Principal investigator 1 PFIZER INC. $1,147.11 02/05/2021 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832884047
Principal investigator 1 GlaxoSmithKline, LLC. $1,007.10 02/01/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809487005
Principal investigator 1 SANOFI PASTEUR INC. $9,183.63 01/21/2021 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
VAD00001 Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers No dispute reported 06/30/2026 838355943
Principal investigator 1 GlaxoSmithKline, LLC. $1,887.30 01/20/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809519093
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 01/13/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486131
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 01/13/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
Not supplied No dispute reported 06/30/2026 809486743
Principal investigator 1 Merck Sharp & Dohme Corporation $15,000.00 01/06/2021 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older No dispute reported 06/30/2026 848761307